ATE238049T1 - Verwendung von kreatinsubstanzen zur behandlung von knochen- und knorpelzellen und geweben - Google Patents

Verwendung von kreatinsubstanzen zur behandlung von knochen- und knorpelzellen und geweben

Info

Publication number
ATE238049T1
ATE238049T1 AT98942645T AT98942645T ATE238049T1 AT E238049 T1 ATE238049 T1 AT E238049T1 AT 98942645 T AT98942645 T AT 98942645T AT 98942645 T AT98942645 T AT 98942645T AT E238049 T1 ATE238049 T1 AT E238049T1
Authority
AT
Austria
Prior art keywords
creatine
tissues
substances
bone
cartilage cells
Prior art date
Application number
AT98942645T
Other languages
English (en)
Inventor
Theo Wallimann
Isabel Gerber
Original Assignee
Synthes Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthes Ag filed Critical Synthes Ag
Application granted granted Critical
Publication of ATE238049T1 publication Critical patent/ATE238049T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3821—Bone-forming cells, e.g. osteoblasts, osteocytes, osteoprogenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0015—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3817—Cartilage-forming cells, e.g. pre-chondrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3843—Connective tissue
    • A61L27/3847—Bones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3843—Connective tissue
    • A61L27/3852—Cartilage, e.g. meniscus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Surgery (AREA)
  • Molecular Biology (AREA)
  • Materials Engineering (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
AT98942645T 1998-07-28 1998-07-28 Verwendung von kreatinsubstanzen zur behandlung von knochen- und knorpelzellen und geweben ATE238049T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1998/004713 WO2000006150A1 (en) 1998-07-28 1998-07-28 Use of creatine compounds for treatment of bone or cartilage cells and tissues

Publications (1)

Publication Number Publication Date
ATE238049T1 true ATE238049T1 (de) 2003-05-15

Family

ID=8167021

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98942645T ATE238049T1 (de) 1998-07-28 1998-07-28 Verwendung von kreatinsubstanzen zur behandlung von knochen- und knorpelzellen und geweben

Country Status (10)

Country Link
US (2) US20020039567A1 (de)
EP (1) EP1100488B1 (de)
JP (1) JP4778143B2 (de)
AT (1) ATE238049T1 (de)
CA (1) CA2338712C (de)
DE (1) DE69813908T2 (de)
DK (1) DK1100488T3 (de)
ES (1) ES2198067T3 (de)
PT (1) PT1100488E (de)
WO (1) WO2000006150A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242491B1 (en) * 1999-06-25 2001-06-05 Rima Kaddurah-Daouk Use of creatine or creatine compounds for skin preservation
US7005274B1 (en) 1999-09-15 2006-02-28 Migenix Corp. Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass
US6811776B2 (en) 2000-12-27 2004-11-02 The Regents Of The University Of Michigan Process for ex vivo formation of mammalian bone and uses thereof
WO2001048148A1 (en) * 1999-12-28 2001-07-05 The Regents Of The University Of Michigan Process for ex vivo formation of mammalian bone and uses thereof
US20080152629A1 (en) * 2000-12-06 2008-06-26 James Edinger Placental stem cell populations
US7311904B2 (en) * 2001-02-14 2007-12-25 Anthrogenesis Corporation Tissue matrices comprising placental stem cells, and methods of making the same
DK1349918T3 (da) 2000-12-06 2014-11-10 Anthrogenesis Corp Fremgangsmåde til indsamling af stamceller fra moderkagen
US7311905B2 (en) * 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
WO2002060315A2 (en) * 2001-01-30 2002-08-08 Orthogene, Inc. Compositions and methods for the treatment and repair of defects or lesions in articular cartilage using synovial-derived tissue or cells
IL157350A0 (en) * 2001-02-14 2004-02-19 Anthrogenesis Corp Post-partum mammalian placenta, its use and placental stem cells therefrom
KR20050075507A (ko) * 2004-01-15 2005-07-21 재단법인서울대학교산학협력재단 시클로크레아틴을 포함하는 골대사성 질환의 예방 및치료를 위한 조성물
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
US7736669B2 (en) * 2004-11-30 2010-06-15 University Of Washington Porous structures, and methods of use
JP4914594B2 (ja) * 2005-09-29 2012-04-11 ユニテックフーズ株式会社 関節痛改善用食品組成物
AU2006304277B2 (en) 2005-10-13 2012-07-05 Celularity Inc. Immunomodulation using placental stem cells
KR20080084808A (ko) 2005-11-17 2008-09-19 바이오미메틱 세라퓨틱스, 인크. ｒｈＰＤＧＦ-ＢＢ 및 생체적합성 매트릭스를 사용하는상악안면골 보강
ES2671355T3 (es) 2005-12-29 2018-06-06 Anthrogenesis Corporation Poblaciones de células madre placentarias
US8455250B2 (en) 2005-12-29 2013-06-04 Anthrogenesis Corporation Co-culture of placental stem cells and stem cells from a second source
JP2009524826A (ja) 2006-01-26 2009-07-02 ザ ユニヴァーシティー オブ テキサス 撮像のための方法及び装置
ES2427993T3 (es) 2006-02-09 2013-11-05 Biomimetic Therapeutics, Llc Composiciones y métodos para el tratamiento de hueso
WO2007126924A1 (en) * 2006-03-28 2007-11-08 University Of South Carolina Method for stimulating proteoglycan synthesis in cells
WO2007146123A2 (en) * 2006-06-09 2007-12-21 Anthrogenesis Corporation Placental niche and use thereof to culture stem cells
US9642891B2 (en) 2006-06-30 2017-05-09 Biomimetic Therapeutics, Llc Compositions and methods for treating rotator cuff injuries
US9161967B2 (en) 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
WO2008073628A2 (en) 2006-11-03 2008-06-19 Biomimetic Therapeutics, Inc. Compositions and methods for arthrodetic procedures
DE102007004781A1 (de) 2007-01-31 2008-08-07 Alzchem Trostberg Gmbh Verwendung von Guanidinoessigsäure(-Salzen) zur Herstellung eines gesundheitsfördernden Mittels
SI2120977T1 (sl) 2007-02-12 2014-01-31 Anthrogenesis Coroporation Zdravljenje vnetnih bolezni z uporabo placentarnih matičnih celic
JP4818177B2 (ja) * 2007-03-27 2011-11-16 ユニテックフーズ株式会社 高齢者向け骨・筋肉増強促進組成物
JP5157007B2 (ja) * 2007-05-11 2013-03-06 ビーエイチエヌ株式会社 骨強化剤
TWM322542U (en) * 2007-05-23 2007-11-21 Universal Scient Ind Co Ltd Testing machine
WO2009002913A1 (en) * 2007-06-22 2008-12-31 Avicena Group, Inc. Use of creatine compounds to treat dermatitis
DE102007030495A1 (de) 2007-06-30 2009-01-15 Alzchem Trostberg Gmbh Verwendung einer eine Kreatin-Komponente enthaltende Zusammensetzung zur Verbesserung der Gedächtnisleistung, der Merkfähigkeit, des Langzeitgedächtnisses und zur Vorbeugung geistiger Ermüdungszustände
RS53841B1 (sr) 2007-09-28 2015-06-30 Anthrogenesis Corporation Supresija tumora korišćenjem humanog placentalnog perfuzata i intermedijernih ćelija ubica poreklom iz humane placente
DE102007053369A1 (de) 2007-11-09 2009-07-02 Alzchem Trostberg Gmbh Verwendung einer eine Kreatin-Komponente enthaltende Zusammensetzung zur Verbesserung der männlichen Fruchtbarkeit
DE102007062288A1 (de) 2007-12-21 2009-06-25 Alzchem Trostberg Gmbh Kreatin-Zubereitung und Verfahren zu deren Herstellung
AU2009212151C1 (en) 2008-02-07 2015-09-17 Stryker Corporation Compositions and methods for distraction osteogenesis
DK2330889T3 (en) 2008-08-20 2017-01-30 Anthrogenesis Corp Improved cell composition and process for making the same
KR20180108887A (ko) * 2008-08-20 2018-10-04 안트로제네시스 코포레이션 단리된 태반 세포를 사용한 뇌졸중 치료
MX2011001992A (es) 2008-08-22 2011-03-29 Anthrogenesis Corp Metodos y composiciones para el tratamiento de defectos oseos con poblaciones de celulas placentarias.
MX2011002555A (es) 2008-09-09 2011-08-03 Biomimetic Therapeutics Inc Composiciones de factor de crecimiento derivadas de plaquetas y metodo para el tratamiento de lesiones de tendon y ligamentos.
US7874536B2 (en) * 2008-09-26 2011-01-25 Groover David O Angle ceiling hanger or bracket
CA2743566C (en) * 2008-11-19 2021-11-09 Anthrogenesis Corporation Amnion derived adherent cells
NZ602569A (en) * 2008-11-21 2014-03-28 Anthrogenesis Corp Treatment of diseases, disorders or conditions of the lung using placental cells
WO2011094181A1 (en) * 2010-01-26 2011-08-04 Anthrogenesis Corporation Treatment of bone-related cancers using placental stem cells
WO2011103598A1 (en) 2010-02-22 2011-08-25 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods for the treatment of tendinopathies
SI2556145T1 (sl) 2010-04-07 2017-01-31 Anthrogenesis Corporation Angiogeneza z uporabo placentnih matičnih celic
AU2011237743A1 (en) 2010-04-08 2012-11-01 Anthrogenesis Corporation Treatment of sarcoidosis using placental stem cells
WO2011154413A1 (en) * 2010-06-07 2011-12-15 Fritz-Lipmann-Insitut E. V. Leibniz-Institut Für Altersforschung Agent against glucocorticoid-induced osteoporosis
CN107828727A (zh) 2010-07-13 2018-03-23 人类起源公司 产生自然杀伤细胞的方法、由此获得的细胞群体及其用途
JP5756614B2 (ja) * 2010-11-02 2015-07-29 花王株式会社 オートインデューサー−２阻害剤、並びに齲蝕病の予防及び／又は治療剤
AR093183A1 (es) 2010-12-31 2015-05-27 Anthrogenesis Corp Aumento de la potencia de celulas madre de placenta usando moleculas de arn moduladoras
US9157908B2 (en) 2011-04-22 2015-10-13 University Of Washington Through Its Center For Commercialization Chitosan-alginate scaffold cell culture system and related methods
EP3443968A1 (de) 2011-06-01 2019-02-20 Celularity, Inc. Schmerzbehandlung mithilfe von stammzellen aus der plazenta
WO2013055476A1 (en) 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
CN102897735B (zh) * 2012-11-12 2014-07-16 中国科学院上海硅酸盐研究所 微波辅助制备羟基磷灰石空心球
AU2014215458A1 (en) 2013-02-05 2015-08-13 Anthrogenesis Corporation Natural killer cells from placenta
EP3151847B1 (de) 2014-06-04 2020-07-29 Cedars-Sinai Medical Center Menschliche mesenchymale stammzellen und pth zur verwendung in einem verfahren zur nichtchirurgischen reparatur von wirbelkompressionsbrüchen
EP3415527B1 (de) 2017-06-14 2025-12-10 Kymab Ltd. Verwendung der extrazellulären domäne des transferrinrezeptor 2 zur diagnostik und behandlung von primär und sekundär sklerosierenden erkrankungen
CN112236166A (zh) * 2018-06-13 2021-01-15 科马布有限公司 用于治疗骨疾病的转铁蛋白受体-2的拮抗剂和激动剂
KR20250006398A (ko) * 2023-07-03 2025-01-13 주식회사 미토스테라퓨틱스 L-아스파르트산을 유효성분으로 포함하는 근세포 또는 조골세포 분화 촉진용 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
US4647453A (en) * 1984-10-18 1987-03-03 Peritain, Ltd. Treatment for tissue degenerative inflammatory disease
US4772591A (en) * 1985-09-25 1988-09-20 Peritain, Ltd. Method for accelerated wound healing
US5693615A (en) * 1991-06-05 1997-12-02 The Procter & Gamble Company Therapeutic compositions for osteoinduction
JPH05238929A (ja) * 1992-02-27 1993-09-17 Sumitomo Pharmaceut Co Ltd 代謝性骨疾患治療用長期持続性製剤
JPH07157439A (ja) * 1993-12-07 1995-06-20 Eisai Co Ltd 骨内部埋め込み用製剤
EP1719510A1 (de) * 1994-11-08 2006-11-08 Avicenda Group, Inc. Verwendung von Kreatin oder Kreatinanalogen zur Behandlung von Erkrankungen des Nervensystems
DE69637104T2 (de) * 1995-02-20 2008-01-31 Yukio Kato Heilmittel für arthrosis deformans und entzündliche gelenkerkrankungen
EP0830149A1 (de) * 1995-06-06 1998-03-25 Osteogenics Inc. Bioverträgliche hydroxyapatitformulierungen und ihre verwendung
DE19529223A1 (de) * 1995-08-09 1997-02-13 Boehringer Mannheim Gmbh Verwendung von Plasminogenaktivatoren zum lokalen Knochenaufbau
DE69628025T2 (de) * 1995-10-11 2004-04-01 Avicena Group, Inc., Cambridge Verwendung von kreatinanalogen zur behandlung von störungen des glukosemetabolismus
US5998457A (en) * 1995-10-26 1999-12-07 Avicena Group, Inc. Creatine analogues for treatment of obesity
AU3214797A (en) * 1996-05-28 1998-01-05 Regents Of The University Of Michigan, The Engineering oral tissues
US5716926A (en) * 1996-07-26 1998-02-10 Paxton K. Beale Composition of pyruvate and protein and method for increasing protein concentration in a mammal
US5756469A (en) * 1996-07-26 1998-05-26 Beale; Paxton K. Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal
WO1998015273A1 (en) * 1996-10-10 1998-04-16 The General Hospital Corporation Photodynamic therapy for the treatment of osteoarthritis
US5888553A (en) * 1997-04-08 1999-03-30 Infinity, Inc. Non-steroidal anabolic composition
US5886040A (en) * 1997-06-17 1999-03-23 Amt Labs, Inc. Creatine pyruvate salt with enhanced palatability
EP0891719A1 (de) * 1997-07-14 1999-01-20 N.V. Nutricia Narungszusammensetzungen mit Gehalt an Methionin

Also Published As

Publication number Publication date
JP4778143B2 (ja) 2011-09-21
DK1100488T3 (da) 2003-08-11
PT1100488E (pt) 2003-09-30
CA2338712C (en) 2012-10-09
HK1037910A1 (en) 2002-02-22
ES2198067T3 (es) 2004-01-16
CA2338712A1 (en) 2000-02-10
DE69813908T2 (de) 2004-02-05
JP2002521440A (ja) 2002-07-16
EP1100488A1 (de) 2001-05-23
DE69813908D1 (de) 2003-05-28
EP1100488B1 (de) 2003-04-23
US20020039567A1 (en) 2002-04-04
WO2000006150A1 (en) 2000-02-10
US20050085543A1 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
ATE238049T1 (de) Verwendung von kreatinsubstanzen zur behandlung von knochen- und knorpelzellen und geweben
Granströ et al. Bone-anchored reconstruction of the irradiated head and neck cancer patient
Leung et al. Complex tibial fracture outcomes following treatment with low-intensity pulsed ultrasound
TWI306407B (en) Apparatus and method for generating an electrical signal for use in biomedical applications
DE69427947D1 (de) Verwendung von teilchen eines bioverträglichen und bioresorbierbaren kalziumsalzes als wirkstoff in der herstellung eines arzneimittels zur lokalen behandlung von entkalkungskrankheiten
DE69533176D1 (de) Verwendung von fibroblastwachstumsfaktoren zur stimulierung des knochenwachstums
Ueda et al. Effect of hyperbaric oxygen therapy on osseointegration of titanium implants in irradiated bone: a preliminary report.
Johnsson et al. The effects of hyperbaric oxygenation on bone-titanium implant interface strength with and without preceding irradiation.
Kerr et al. The effect of ultrasound on bone dimensional changes following extraction: a pilot study
Marker et al. Osseointegrated implants for prosthetic rehabilitation after treatment of cancer of the oral cavity
Cohen et al. Mandibular reconstruction
Freitas et al. Effect of therapeutic pulsed ultrasound on lipoperoxidation and fibrogenesis in an animal model of wound healing
Teichgraeber et al. Skin grafts in intraoral reconstruction: A new stenting method
Cummings Experimental observations of canine mandibular regeneration following segmental removal, freezing, and reimplantation
RU2359621C1 (ru) Способ хирургического лечения рака гортани
RU2250789C2 (ru) Способ лечения повреждений костей при замедленной консолидации
RU2225212C2 (ru) Способ стимуляции дистракционного регенерата
RU2180534C2 (ru) Способ хирургического лечения травматических повреждений костей
Marciani et al. Cancellous-marrow bone grafts in irradiated tissue
RU2284785C1 (ru) Способ лечения юношеского эпифизеолиза головки бедренной кости у детей
Goncharov et al. The use of Hydroxyapol in filling in bone defects of the jaws and stimulating osteogenesis
Esterhai The electrical stimulation of osteogenesis
RU2179417C1 (ru) Способ хирургического лечения дефекта альвеолярной кости при пародонтите
SU1641364A1 (ru) Способ стимул ции остеогенных свойств аутоспонгиозы
RU1775913C (ru) Способ лечения больных в раннем послеоперационном периоде после уранопластики

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1100488

Country of ref document: EP

EEFA Change of the company name
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee